Canadian Respiratory Journal (Jan 2004)

The Canadian Optimal Therapy of COPD Trial: Design, Organization and Patient Recruitment

  • Shawn D Aaron,
  • Katherine Vandemheen,
  • Dean Fergusson,
  • Mark FitzGerald,
  • Francois Maltais,
  • Jean Bourbeau,
  • Roger Goldstein,
  • Andrew McIvor,
  • Meyer Balter,
  • Denis O'Donnell

DOI
https://doi.org/10.1155/2004/394710
Journal volume & issue
Vol. 11, no. 8
pp. 581 – 585

Abstract

Read online

BACKGROUND: There are no published studies that have assessed whether adding long-acting beta 2-agonist bronchodilators and/or inhaled steroids to chronic therapy with tiotropium would provide additional clinical benefit to patients with moderate to severe chronic obstructive pulmonary disease (COPD).